ViEL-T is actively developing and platformizing new and innovative therapeutic technologies and research models to create treatments that can combat both current and emerging RNA viruses and viral infectious diseases.
By developing therapeutic technologies that can rapidly respond to new and evolving viruses in the future, ViEL-T aims to take responsibility for safeguarding human health.
Key Pipeline
| Pipeline | Type | Target | R&D | Pre-clinical development | Clinical development | ||||
|---|---|---|---|---|---|---|---|---|---|
| Target & Drug-centered |
Lead optimization |
Efficacy | Toxicity | Phase 1 | Phase 2 | Phase 3 | |||
| Dikovir(antivirals) | single chemical compound |
SARS-CoV-2 | |||||||
| Didoxvir(antivirals) | single chemical compound |
Hepatitis C Virus | |||||||
| SEPWAR5 (antivirals) |
LncRNA | Hepatitis C Virus | |||||||
| ASLI01419 (anti-cancer medicine) |
LncRNA | Hepatocellular carcinoma |
|||||||
| CRC-1 (antiviral platform) |
CRISPR/Cas13 mRNA |
SARS-CoV-2 | |||||||
